For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesMarch 2016
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions and individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives and other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.

Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213


Glimcher Named Dana-Farber President
Laurie H. Glimcher, MD, an internationally recognized immunologist, has been named the next president and CEO of Dana-Farber Cancer Institute. Dr. Glimcher is currently the Stephen and Suzanne Weiss Dean of the Medical College at Weill Cornell Medicine in New York City, where she is also professor of medicine and provost for medical affairs at Cornell University. Dr. Glimcher will begin at Dana-Farber in January 2017, and current President Edward J. Benz, Jr., MD, has agreed to remain as president until her arrival. more...

Call for Abstracts for the 8th Annual AACI CRI Meeting

The AACI Clinical Research Initiative (CRI) is soliciting abstracts for presentation at the 8th Annual CRI Meeting that will be held on July 20-21, 2016, in Chicago, IL. The purpose of the abstracts is to inform the CRI meeting audience about clinical trials operational challenges and solutions implemented at the cancer centers. more...

Registration is Open for Annual Hill Day
Register today to attend AACI's annual Hill Day on Thursday, May 12, 2016, in Washington, DC. Advocates will head to Capitol Hill to thank Members of Congress for their renewed commitment to the National Institutes of Health (NIH) and the National Cancer Institute (NCI) in Fiscal Year 2016 and to request a robust investment for these agencies in Fiscal Year 2017 and beyond. more...

Cancer Research Policy Forum to be Held at Moffitt Cancer Center
The American Association for Cancer Research and Moffitt Cancer Center, with support from U.S. Representatives Gus Bilirakis (FL-12) and Kathy Castor (FL-14) and the Association of American Cancer Institutes, will host a forum on March 7, 2016, at Moffitt Cancer Center in Tampa, Florida. The forum will feature National Cancer Institute Acting Director Douglas R. Lowy, MD.

The event will be streamed live. To register for the event please visit: more...

News from the Centers
Awards & Honors
Study on Increasing Minority Participation in Clinical Trials Among Best in Cancer Research
UAB Comprehensive Cancer Center
Research led by Mona Fouad, MD, MPH, director of the UAB Division of Preventive Medicine, has been selected by the American Society of Clinical Oncology for inclusion in Clinical Care Advances 2016, the Society's annual review of progress against cancer and emerging trends in the field. The study, titled "Patient navigation as a model to increase minority participation in cancer clinical trials," examines the use of patient navigators for informing and enrolling potentially eligible African-American patients in clinical trials. more...
Grants & Gifts
Study Aims to Resolve How To Manage Pre-Cancers of the Breast
Duke Cancer Institute
The first large U.S. study aimed at resolving an ongoing debate about the best way to treat an early sign of breast cancer will launch later this year under the direction of a Duke Cancer Institute investigator E. Shelley Hwang, MD. The study, entitled COMET (Comparison of Operative to Medical Endocrine Therapy) for low-risk ductal carcinoma in situ, received funding through a $13.4 million, five-year award from the Patient-Centered Outcomes Research Institute (PCORI), an independent, nonprofit organization authorized by Congress in 2010 to support research that enlightens health care decisions. more...
Teams Awarded Nearly $7 Million in Research Funding
Roswell Park Cancer Institute
Investigators at Roswell Park Cancer Institute have garnered nearly $7 million in recent research grants. The awards include a five-year, $2.4 million grant from the National Cancer Institute to optimize a particular approach for administering photodynamic therapy, a form of cancer therapy that was developed at Roswell Park in the 1970s. more...
Wicha Receives $6.5M Grant to Target Cancer Stem Cells
University of Michigan Comprehensive Cancer Center
Max S. Wicha, MD, founding director emeritus of the University of Michigan Comprehensive Cancer Center, has received a $6.5 million Outstanding Investigator Award to study cancer stem cells, the small number of cells within a tumor that fuel its growth and spread. The award - roughly three times a traditional individual investigator award - is part of a new grant program called R-35 developed by the National Cancer Institute. more...
Leadership Transitions
Ernstoff to Assume Leadership Roles at UB, Roswell Park
Roswell Park Cancer Institute
Marc S. Ernstoff, MD, has been appointed professor and chief of the Division of Hematology/Oncology in the Department of Medicine in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB), and chair of the Department of Medicine and senior vice president of clinical investigation at Roswell Park Cancer Institute. The appointments take effect on April 1. more...
McConkey Named Director of Bladder Cancer Institute
Sidney Kimmel Comprehensive Cancer Center
David J. McConkey, PhD, has been appointed director of the Johns Hopkins Greenberg Bladder Cancer Institute, whose members include experts from the Sidney Kimmel Comprehensive Cancer Center, the James Buchanan Brady Urological Institute, and the School of Medicine's departments of Radiation Oncology and Molecular Radiation Sciences, Surgery, and Pathology. The institute was established in 2014 with a $15 million gift from Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife, Stephanie Cooper Greenberg, and a $30 million investment from Johns Hopkins University. more...
Radiation Oncologist Joins State Task Force on Prostate Cancer
Fox Chase Cancer Center, Temple Health
Eric M. Horwitz, MD, chair of radiation oncology at Fox Chase Cancer Center, has been appointed to the Pennsylvania Task Force on Prostate Cancer and Related Chronic Prostate Conditions by Pennsylvania Secretary of Health Dr. Karen Murphy. Dr. Horwitz joins other radiation oncologists, registered nurses, urologists, state health officials, and prostate cancer patients tasked with investigating, raising awareness and making recommendations concerning prostate cancer and related conditions. more...
Gwede Appointed to Florida Cancer Control and Research Advisory Council
Moffitt Cancer Center
Clement K. Gwede, PhD, MPH, RN, associate member of the Health Outcomes and Behavior Program at Moffitt Cancer Center, has been appointed to the Florida Cancer Control and Research Advisory Council. Dr. Gwede has served as Associate Director for Diversity at Moffitt since 2005, with emphasis on patient diversity initiatives and minority participation in clinical research. more...
Pickett Joins Moffitt as Chief Philanthropy Officer to Lead the Foundation
Moffitt Cancer Center
Moffitt Cancer Center has announced the hire of Kevin Pickett, MBA, CFP®, as its Executive Vice President & Chief Philanthropy Officer. Pickett will provide the strategic vision for the role of philanthropy at Moffitt, working closely with executive leadership to identify and define the institution's philanthropic priorities. Prior to Moffitt, Pickett served as Executive Director of Development for The University of Texas MD Anderson Cancer Center. more...
Warner Named to Vanderbilt Cancer Registry Leadership Post
Vanderbilt-Ingram Cancer Center
Jeremy Warner, MD, MS, has been named medical director of the Vanderbilt Cancer Registry at Vanderbilt-Ingram Cancer Center (VICC). In this newly created position, Warner will work closely with Dauphne McGavic, RN, MSN, CTR, who recently was appointed program manager of the Registry. The Vanderbilt Cancer Registry was founded in the mid-1930s and is the official repository for data about cancer cases at VICC. more...
Research Highlights
Pinpointing the Chromosomal Creation of Cancer
University of Kansas Cancer Center
While researchers are now familiar with how cancer begins-cells mutate and then multiply wildly out of control-it is still uncertain exactly how that mutation starts in the molecules of the cells. Yoshiaki Azuma, PhD, a member of the Cancer Biology Research Program at The University of Kansas Cancer Center, is analyzing the role of an enzyme called Topoisomerase II (Topo II) and how it may affect the stability of genomes. Genomic instability, or a large amount of mutations with the genome of a cell, is a basic cause of cancer. more...
Cancers of Unknown Origin Put Family Members At Increased Risk
Huntsman Cancer Institute
Cancer usually begins in one location and then spreads, but in 3-5% of cancer patients, the tissue where a cancer began is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months. A new study finds that family members of CUP patients are at higher risk of developing CUP themselves, as well as cancers of the lung, pancreas, colon, and some cancers of the blood. Jewel Samadder, MD, is the lead researcher on the University of Utah and Huntsman Cancer Institute study. more...
Researchers Propose New Staging for HPV-related Oropharyngeal Cancer
University of Texas MD Anderson Cancer Center
Human papillomavirus (HPV) status is a strong predictor of prognosis for patients with oropharyngeal carcinoma (OPC), but the current staging system does not adequately account for biological and clinical differences between HPV-positive OPC and HPV-negative OPC, commonly caused by alcohol and tobacco use. With rates of HPV-related OPC rising rapidly, researchers at The University of Texas MD Anderson Cancer Center propose a new staging system to more accurately predict patient outcomes and identify the most appropriate treatments. more...
Laser Surgery Opens Blood-Brain Barrier to Chemotherapy
Siteman Cancer Center
Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain's protective cover, enabling them to deliver chemotherapy drugs to patients with a form of deadly brain cancer. In a pilot study, 14 patients with glioblastoma - the most common and aggressive type of brain cancer - underwent minimally invasive laser surgery to treat a recurrence of their tumors. Heat from the laser is known to kill brain tumor cells but, unexpectedly, the researchers found that the technology can penetrate the blood-brain barrier. Eric C. Leuthardt, MD, a Siteman Cancer Center member, was co-corresponding author on the study. more...
Chemoradiation May Improve Survival for a Subset of Head and Neck Cancer Patients
University of Colorado Cancer Center
The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to University of Colorado Cancer Center research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. While previous research has demonstrated the efficacy of combining CT with RT to improve survival for HNSCC patients, this improvement had not been shown in patients older than 70 years. Sana Karam, MD, PhD, is senior author on the study. more...
Clinical Trial Offers New Drug Combo to Fight Lung Cancer
University of New Mexico Comprehensive Cancer Center
Yanis Boumber, MD, PhD, has just opened the first of more than 10 new lung cancer clinical trials at the UNM Comprehensive Cancer Center. The phase 3 clinical trial, called "Neptune," compares a combination of two immune drugs with standard chemotherapy as a first line lung cancer treatment. Data from phases 1 and 2 of the trial showed that nearly half of patients responded to the combo, many with long-lived responses. The trial is currently recruiting and Dr. Boumber is in the process of opening nine more trials. more...
Chemotherapy Better Option for Pancreatic Cancer Surgery Patients
Vanderbilt-Ingram Cancer Center
A multicenter study led by Vanderbilt University Medical Center investigators found that pancreatic cancer patients who underwent surgery and received chemotherapy lived longer and had fewer cancer recurrences in other parts of the body than patients who also received chemoradiation therapy. The study was led by Alexander Parikh, MD, MPH, FACS. more...
New Clues to Common and Elusive KRAS Cancer Gene
University of Michigan Comprehensive Cancer Center
Researchers at the University of Michigan Comprehensive Cancer Center have dug deeper and exposed a key interaction that may contribute to why mutations in KRAS lead to cancer. AGO2 plays a role in silencing genes and processing microRNA - so it impacts many genes. The researchers found AGO2 interacted with both mutated and normal KRAS. The link appeared in all 12 of the cell lines tested. more...
Time Between Positive Fecal Blood Test and Colonoscopy Varies Widely
American Association for Cancer Research
Patients who received positive fecal blood test results as part of the screening process for colorectal cancer experienced wide variations in the time between a positive result and a follow-up colonoscopy across four U.S. health care systems, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The study's lead author is Jessica Chubak, PhD. more...
Protein Identified that Plays Key Role in Brain Cancer Stem Cell Growth and Survival
UAB Comprehensive Cancer Center
A team of physicians and scientists at the University of Alabama at Birmingham have discovered that a kinase protein, mixed lineage kinase 4, also known as MLK4, plays a crucial role in survival of patient-derived brain cancer stem cells in pre-clinical animal models. The findings suggest that MLK4 could potentially be a useful target for cancer treatment. more...
Assessing the Role of Autophagy in Prostate Cancer
Rutgers Cancer Institute of New Jersey
Research from investigators at Rutgers Cancer Institute of New Jersey and the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, shows the intracellular process of autophagy plays a role in the development of prostate cancer. Rutgers Cancer Institute Deputy Director Eileen P. White, PhD, and Rutgers Cancer Institute Director Robert S. DiPaola, MD, are the co-corresponding authors of the work. more...
Breast Cancer Survivors Vulnerable for Thyroid Tumors, and Vice Versa
The University of Chicago Medicine Comprehensive Cancer Center
Women who survive either breast or thyroid cancer may be at increased risk for the other tumor type, according to a new analysis. University of Chicago researchers who reviewed 37 published studies found breast cancer survivors were 1.55 times more likely to develop thyroid cancer than women who hadn’t had breast cancer. And, female thyroid cancer survivors were 1.18 times more likely to get breast cancer than women who hadn’t had thyroid cancer. The study’s lead author is Raymon Grogan, MD. more...
First-In-Class Drug ONC201 Shows Potential for Some Blood Cancers
University of Texas MD Anderson Cancer Center
NC201, an anti-cancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers including mantle cell lymphoma (MCL) and acute myeloid leukemia (AML), according to a recent clinical study. A research team led by Michael Andreeff, MD, PhD, found that ONC201, which is in early clinical trials, caused cell death even when a crucial protein known as p53 is mutated or deleted entirely. more...
Washington University Leads Effort to Improve Radiation Therapy for Vets
Siteman Cancer Center
Washington University School of Medicine in St. Louis has been selected to lead national efforts to improve and standardize radiation therapy for veterans with cancer. The goal is to ensure that veterans across the U.S. receive the same high-quality radiation therapy at any of the 40 Veterans Health Administration radiation oncology centers nationwide. Working with the American Society for Radiation Oncology, Washington University radiation oncologists - members of Siteman Cancer Center - are developing a system to provide continuous feedback on the progress, quality and safety of each veteran's cancer therapy. more...
Alternative Proteins Encoded by Same Gene Have Widely Divergent Functions
UC San Diego Moores Cancer Center
A single human gene can produce many different proteins. In the first large-scale study of its kind, researchers at University of California, San Diego School of Medicine, Dana-Farber Cancer Institute and McGill University report that most of these sibling proteins encoded by the same gene - known as protein isoforms - often play radically different roles within tissues and cells. more...
New Nonalcoholic Fatty Liver Disease Research Center Launched
UC San Diego Moores Cancer Center
Roughly one-quarter of all Americans - an estimated 100 million adults and children - have nonalcoholic fatty liver disease (NAFLD), a chronic condition that can lead to cirrhosis, liver cancer and liver failure. Combining a diverse array of basic science, biomarkers, imaging and clinical efforts, University of California, San Diego School of Medicine has launched a new NAFLD Research Center to better understand the disease and develop treatments where none currently exist. Rohit Loomba, MD, is the center's director. more...
UCSF Opens Center on BRCA Research
UCSF Helen Diller Family Comprehensive Cancer Center
Scientists know that people who carry an inherited gene mutation, like BRCA1 or BRCA2, have an increased risk of developing cancer, one driven more by the biology of the cells in their bodies and less by the organ in which their cancer arises. When cancer develops, it often occurs at a younger age and these women and men can respond differently to cancer therapies. They also have a higher chance of developing another type of cancer. The mission of the Center for BRCA Research is to provide a central resource for families with BRCA and other mutations to receive personalized care and planning for their long-term health and well-being. This is our opportunity to rethink how we treat and manage hereditary cancers. more...
Increased Treatments, Cost and Side Effects do Little to Increase Advanced Colorectal Cancer Survival
University of Colorado Cancer Center
A new study shows that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2 percent to 53 percent. During this period, 1-year treatment cost increased 32 percent to reach an estimated $2.2 billion annually. However, median survival for these patients increased by only one month. Cathy J. Bradley, PhD, is first author on the study. more...
Immune Therapy for Brain Tumors: A New Promising Avenue
University of New Mexico Comprehensive Cancer Center
Olivier Rixe, MD, PhD, serves as a National Principal Investigator for clinical trials testing the combination of temozolomide, alkylating agents, and indoximod, a new immunotherapy drug. He is working closely with a team of physicians at the UNM Cancer Center to conduct these trials: M. Omar Chohan, MD, a neurosurgeon who specializes in surgery for tumors of the brain and spinal cord; Gregory Gan, MD, PhD, a radiation oncologist who is an expert in the radiation therapy of brain tumors; and Yanis Boumber, MD, PhD, a newly recruited medical oncologist to the UNM Cancer Center who is an expert in cancers of the lung, brain and spinal cord, and early phase clinical trials. more...
Depressed Patients at Higher Risk for Complications, Hospital Readmission after Complex Cancer Surgery
University of Pittsburgh Cancer Institute
Cancer patients who report significant symptoms of depression before undergoing a complex abdominal surgery are at increased risk of postoperative complications and unplanned hospital readmissions, according to a University of Pittsburgh Cancer Institute study headed by Carissa Low, PhD. more...
Two Forms of Radiosurgery for Brain Metastases are Equally Effective
Sidney Kimmel Cancer Center at Thomas Jefferson University
While two advanced radiosurgery approaches - Gamma Knife and RapidArc® - offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center. Their study compared the two different devices in brain radiosurgery. Six patients, each with three or four brain metastases, were studied. more...
Cancer Screening Technology Advanced to Boost Personalize Cancer Treatment
Jonsson Comprehensive Cancer Center, UCLA
Despite a growing interest in developing non-invasive methods to identify rare cancer cells or cancer cell DNA in blood, current techniques remain complicated and often prohibitively expensive. Now, UCLA researchers have pioneered a more effective approach to these "liquid biopsies" that has the potential to offer a streamlined and low-cost solution for people with the disease. Dino Di Carlo, PhD, director of the Jonsson Comprehensive Cancer Center Nanotechnology Program more...
Weight May Influence Outcomes After Lung Cancer Surgery
The University of Chicago Medicine Comprehensive Cancer Center
Lung cancer surgery patients are most likely to have complications and to die if they’re either too thin or fat, a new study suggests. The study included more than 41,000 people who had lung cancer surgery between 2009 and 2014. Patients were categorized according to their body mass index. While the study couldn’t prove cause-and-effect, people who were either underweight or severely obese had the highest rates of complications and death following surgery, according to the study. more...
Injuries, Other Health Concerns, More Common in Older People after Certain Cancer Surgeries
Jonsson Comprehensive Cancer Center, UCLA
Older people who undergo cancer surgery are more likely than their younger counterparts to experience injuries and health issues such as falling down, breaking bones, dehydration, bed sores, failure to thrive and delirium. These age-related issues may lead to longer hospital stays, increased health care costs and a greater risk of death, a UCLA study found. more...
Tricked-Out Immune Cells Could Attack Cancer, Spare Healthy Cells
UCSF Helen Diller Family Comprehensive Cancer Center
UC San Francisco scientists have created a new class of highly customizable biological sensors that can be used to form "logic gates" inside cells of the immune system, giving these cells the capability to home in on and kill a wide range of cancer cells while preventing them from attacking normal tissue. As reported in two companion papers, in addition to their potential to bring much-needed precision and safety to the form of cancer immunotherapy known as CAR T cell therapy, these versatile new sensors, known as synNotch receptors, can also be inserted into cells such as nerve and muscle cells. Wendell A. Lim, PhD, is senior author of the papers. more...
Biologic, Not Chronologic, Age Should Drive Cancer Treatment Choices
The Ohio State University Comprehensive Cancer CenterJames Cancer Hospital & Solove Research Institute
As the boomer generation ages, the number of older adults with blood-based cancers is growing. For many of these patients, the best chance for a "cure" involves intensive treatments traditionally thought to be too harsh for people over age 65. Experts at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, however, say it is a patient's overall "fitness" and biologic age - how their body has aged over time - that should guide treatment choices, not their age in literal calendar years. more...
Combination Therapy May Top Radiotherapy Alone for Aggressive Brain Cancer
Sidney Kimmel Cancer Center at Thomas Jefferson University
Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves. Researchers say their 12-patient study offers enough promise that a more comprehensive, phase 2 clinical trial should be conducted to test the combination therapy for aggressive, recurrent brain cancer. more...
Phone Counseling Insufficient to Help Teens Refrain from Smoking into Young Adulthood
Fred Hutchinson Cancer Research Center
In a 14-year study involving more than 2,000 teen smokers in 50 Washington state high schools, a team of cancer prevention researchers at Fred Hutchinson Cancer Research Center has found that one year of telephone counseling using motivational interviewing and skills training delivered during the senior year of high school is insufficient to help the smokers quit and stay quit up to six years into young adulthood. Arthur V. Peterson Jr., PhD, is principal investigator on the study. more...
Other News
Vice President Biden Visits Duke As Part Of "Moonshot" Initiative
Duke Cancer Institute
Invoking the aspirational spirit that put U.S. astronauts on the moon, Vice President Joe Biden visited Duke Health as part of the national "moonshot" initiative he is leading to advance cancer research. With the Duke Cancer Institute and the Duke University School of Medicine as a backdrop, the vice president cited the unique history of the Research Triangle area, where major universities, biotechnology companies and federal research agencies have long combined forces. He said the area's teamwork demonstrates the sort of collaborative effort that the cancer cure moonshot aims to foster nationwide. more...
Universal Hospital in Abu Dhabi, Fox Chase Sign Agreement
Fox Chase Cancer Center, Temple Health
Fox Chase Cancer Center, Philadelphia, has signed an agreement with Universal Hospital, Abu Dhabi, to design program services as Universal Hospital looks to establish a bone marrow transplant program within the United Arab Emirates. As a follow-up to their Memorandum of Understanding signed last November, representatives from the Philadelphia-based NCI-designated comprehensive cancer center visited the Abu Dhabi facility over three days. Richard I. Fisher, MD, is President and CEO at Fox Chase Cancer Center-Temple Health. more...
First Accredited Trans-Border Medical Physics Residency Program Launched
Barbara Ann Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute, based in Detroit, and the Windsor Regional Hospital Cancer Program, in Windsor, Ontario, have partnered to create the first accredited trans-border Medical Physics Residency Program. Karmanos will lead the program, working collaboratively with the radiation oncology teams at Windsor Regional Cancer Centre and the Karmanos Cancer Institute at McLaren Macomb, Ted B. Wahby Cancer Center, in Mt. Clemens, Michigan. more...
First Patients Receive Therapy at New Maryland Proton Treatment Center
University of Maryland Marlene and Stewart Greenebaum Cancer Center
The University of Maryland School of Medicine has announced that the Maryland Proton Treatment Center has treated its first cancer patients with proton therapy at a new $200 million facility in the University of Maryland BioPark in West Baltimore. The 110,000-square-foot center, which houses a 90-ton cyclotron, is the first in the Eastern U.S. to offer ProBeam® image guided intensity-modulated proton therapy--the most advanced and precise form of radiation therapy. more...
Collaboration Accelerates Research to Aid Development of Blood-based Biomarkers
The Wistar Institute
The Wistar Institute, the nation's first independent biomedical research institute and a National Cancer Institute (NCI)-designated cancer center, and Christiana Care Health System's Helen F. Graham Cancer Center & Research Institute are working together to advance early detection and treatment of cancer. Stemming from this collaboration came a recent announcement by OncoCyte, a developer of novel, non-invasive liquid biopsy products for the early detection of cancer, about its global licensing agreement to acquire exclusive commercial rights to a non-invasive blood test that can be used to detect lung cancer at its earliest stages. more...
Job Opportunities
Director of Clinical Research Operations and Management  
Massey Cancer Center
Virginia Commonwealth University


Director of Administrative Operations  
University of Illinois Cancer Center


Coordinator of Clinical Research Contracts, Clinical Trials Administration  
St. Jude Children's Research Hospital


Meeting Announcements

How the Experts Treat Hematologic Malignancies

March 10, 2016 - 12, 2016
Mandarin Oriental, Las Vegas
Register today:

Given the increasing frequency of Hematologic Malignancy, especially in an aging population, as well as the complexities of individual clinic presentation, there is a need to provide an opportunity for Oncologists, Hematologists and Oncology Nurses to engage in a thoughtful examination and discussion with experts in various hematologic cancers.

CCAF 2016 Spring Meeting

Sunday, April 3 through Tuesday, April 5
The meeting will be held in downtown Fort Worth at the Renaissance Worthington Hotel. A preliminary agenda and meeting registration can be found here:

2016 NACCDO/PAMN Annual Conference

Please join us for the 2016 NACCDO/PAMN Annual Conference from Tuesday, April 5, through Friday, April 8, hosted by City of Hope at the Langham Huntington Hotel in Pasadena, CA. You may register for the conference here.

2016 Capitol Hill Day

AACI will co-host its annual Capitol Hill Day with the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
May 11-12, 2016
Washington, DC
Register to attend today!

8th Annual AACI Clinical Research Initiative Meeting

Save the Date!
July 20-21, 2016
Loews Chicago O'Hare Hotel
Submit your abstract today:

2016 AACI/CCAF Annual Meeting

Save the Date!
October 23-25, 2016
Westin Chicago River North
Chicago, IL